A Korean Beauty Drip’s Licence Says Nothing About Beauty

Note №17REGULATORY RECORD

Korean clinics sell IV drips under nicknames — 백옥주사 (baegok jusa, “white jade injection”), 신데렐라주사 (sinderella jusa, “Cinderella injection”) — rather than product names. We read one glutathione injection’s licence in Korea’s drug database in full on 13 August 2026: its only approved indication is preventing nerve damage caused by cisplatin-type chemotherapy. It does not mention skin. Korea regulates off-label prescribing rather than banning it — the health-insurance rules set out an approval route through the institution’s review board and the review agency. What the gap tells you is that no regulator has evaluated the use being sold to you.

Walk into a Korean clinic for a vitamin drip and you will be offered items with nicknames. 백옥주사 — the “white jade injection.” 신데렐라주사 — the “Cinderella injection.” 마늘주사 — the “garlic injection.” The names describe an outcome, or a smell, and they are what appears on the price board.

None of them is a product name. Each is a nickname for a prescription drug that Korea’s Ministry of Food and Drug Safety licensed for something specific — and in at least one case we were able to read in full, the licence does not mention skin at all.

What is 백옥주사 (baegok jusa) actually licensed for?

백옥주사 is glutathione. We looked up a glutathione injection in the ministry’s own drug database and read its approved indication.

라이트타치온주1200밀리그램 (글루타티온(환원형)) — Mothers Pharmaceutical, licensed 24 January 2017. The approved indication, in full:

시스플라틴 또는 유사계열 화학요법에 의한 신경성질환의 예방

Prevention of neurological disorders caused by cisplatin or similar chemotherapy.

That is the entire licensed indication for 라이트타치온주1200밀리그램. It is a supportive drug for cancer patients on platinum-based chemotherapy, given to protect their nerves. There is no line about pigmentation, brightness, tone, or skin of any kind.

The drug being sold to you as a whitening treatment is licensed to stop chemotherapy from damaging nerves.

This is not an accusation

It needs saying plainly, because the gap above is easy to misread.

Korea regulates prescribing outside a licence rather than prohibiting it. The route is written into the health-insurance rules: under the Rules on the Standards for Medical Care Benefits under National Health Insurance, Article 9(1), what is excluded from benefit coverage is listed in Table 2 — and the Health Insurance Review and Assessment Service publishes the procedure that sits on top of that clause for drugs used beyond their licensed range. As HIRA describes it, the institution clears its own institutional review board, files with HIRA within fifteen days, the Ministry of Food and Drug Safety reviews safety and efficacy, HIRA issues the decision, and the institution reports its usage once a year. A licence reflects what a manufacturer applied and paid to prove, not the boundary of what a substance can do. Nothing here says the injection is unsafe, and nothing here says it does or does not work. We are not in a position to tell you either, and we are not going to guess.

What we did not verify. That procedure is written for drugs used inside the national health insurance system. We did not establish how — or whether — it reaches a purely cosmetic, self-paid drip in a private clinic, and we are not claiming that the drips on a Korean price board have been through it. We are also not claiming that any of them is unlawful.

What the gap does tell you is narrower, and it is still worth carrying:

• The regulator has not evaluated the use you are buying. When a drug is given for its licensed purpose, an agency has reviewed evidence for that purpose. Off-label, that review does not exist. The claim rests on the clinic.
• The marketing language is not regulated language. “Whitening,” “glow,” “detox,” “immunity” are sales words. They do not appear in the licence, and no agency has signed off on them.
• You are the one carrying the difference. Which is a reason to ask what is in the bag, not a reason to walk out.

The nicknames, decoded: what is in a Korean beauty drip?

We are listing what each nickname refers to and what it is marketed for. We are not stating what any of them does.

The last row — 수액 / 링거 — is the one to watch, because it names the container rather than the contents. A “링거” is a base fluid. What matters is what has been added to it, and that is a question, not a menu item.

What we could not check

We read one licence in full — the glutathione injection 라이트타치온주1200밀리그램. We were not able to read the approved indication text for the others.

The ministry’s public database, 의약품안전나라, returns its product-detail pages in a form that does not render without a browser session, so the indication field could not be retrieved for the thioctic acid injection (부광치옥타시드주, Bukwang Pharmaceutical) or for the others in the table. We confirmed those products exist and are injections. We did not read what they are licensed to treat, so we are not telling you.

We are also not telling you that every glutathione injection carries the wording above. We read one product’s licence. Others may be worded differently.

If a number or an indication matters to your decision, the clinic can show you the licence for the specific product it is about to use. That request is ordinary and answerable.

What to ask before the needle

1. “What is the product name, and what is the active ingredient?” The nickname answers neither. This is the same problem we described in Korean clinic menus that list product names rather than treatments.
2. “What is this licensed for in Korea?” Not what it is used for. What the licence says.
3. “Is this being given off-label?” A clinic comfortable with the answer will simply say yes and explain why. That is a better sign than a clinic that does not understand the question.
4. “What is the dose, and what else is in the bag?” Particularly for anything sold as 링거.
5. “Can I have this written down?” You will want it if anything needs following up at home — and you can obtain your records after you fly out.

If a drip is sold to you as part of a prepaid package of sessions, the money side has its own well-documented failure mode — refunds, not complications, are what people actually end up disputing.

Common questions

What is 백옥주사, the “white jade injection”?

It is a nickname, not a product name. The active substance is glutathione, and it is marketed in Korean clinics for brightening or “whitening.” We are describing what it is sold as, not what it does.

Is glutathione licensed for skin whitening in Korea?

The one product we read in full is not. 라이트타치온주1200밀리그램 (Mothers Pharmaceutical, licensed 24 January 2017) carries a single approved indication — prevention of neurological disorders caused by cisplatin or similar chemotherapy — and no mention of skin. We read one product’s licence on 13 August 2026; other glutathione products may be worded differently, and we are not claiming otherwise.

Is it legal for a Korean clinic to give a drip off-label?

Korea regulates off-label use rather than banning it. The health-insurance rules (Rules on the Standards for Medical Care Benefits under National Health Insurance, Article 9(1) and Table 2) sit under a published procedure in which a medical institution clears its own review board, files with the Health Insurance Review and Assessment Service, and receives a decision after the Ministry of Food and Drug Safety reviews safety and efficacy. We did not establish how that procedure applies to a purely cosmetic, self-paid drip. The consequence for a patient is narrower: where a use is off-label, no agency has reviewed evidence for that use, so the claim rests on the clinic rather than on the regulator.

What is in a 링거 (ringgeo) drip?

링거 names the base fluid — saline or a Ringer’s solution — not the contents. What matters is what has been added to it, which is a question for the clinic rather than a line on the price board.

The Clinic Notes — verified, source-cited information on cosmetic medicine in South Korea. We accept no payments or benefits from clinics, hospitals, doctors, or referral agencies.

Sources: Ministry of Food and Drug Safety, 의약품안전나라 (Drug Safety Information system), product licence record for 라이트타치온주1200밀리그램(글루타티온(환원형)), Mothers Pharmaceutical, licensed 24 January 2017 — indication text read in the original, 13 August 2026. Existence and dosage form of 부광치옥타시드주(티옥트산트로메타민), Bukwang Pharmaceutical, confirmed in the same database on the same date; its indication text could not be retrieved. Nicknames and their marketed uses are as advertised by clinics and are not regulator language. Rules on the Standards for Medical Care Benefits under National Health Insurance, Article 9(1), read in the original on the National Law Information Center, 21 August 2026 (https://www.law.go.kr/법령/국민건강보험요양급여의기준에관한규칙). Approval procedure for use beyond a licensed range as described by the Health Insurance Review and Assessment Service, read 21 August 2026 (https://biz.hira.or.kr/contents/html/MP00000730.html).